Article
- Author:
- Neil Osterweil
Publish date: November 20, 2016
NATIONAL HARBOR, MD. – Sex difference in immune regulatory responses may drive the poorer responses to treatment with PD-1 inhibitors se...
Article
- Author:
- Neil Osterweil
Publish date: November 19, 2016
NATIONAL HARBOR, MD. – Density in tumors of two key immune cells may be a biomarker for response to an inhibitor of programmed death-lig...
Article
- Author:
- Neil Osterweil
Publish date: November 5, 2016
BOSTON – The only meaningful measure of the success of biosimilar drugs for arthritis is whether patients use them.
Article
- Author:
- Neil Osterweil
Publish date: November 5, 2016
BOSTON – Biosimilar drugs are not identical twins of original biologic agents, but there are very strong family ties, and the newcomer is expected ...
Article
- Author:
- Neil Osterweil
Publish date: November 4, 2016
BOSTON – For rheumatologists, the primary selling points of biosimilar agents are their presumed efficacy and safety, and their promised cost savin...
Article
- Author:
- Neil Osterweil
Publish date: October 18, 2016
The selective estrogen receptor degrader fulvestrant continues to offer improved progression-free survival compared with the aromatase inhibitor an...
Article
- Author:
- Neil Osterweil
Publish date: October 17, 2016
Pembrolizumab was superior to chemotherapy in stage IV NSCLC with PD-L1 expression of 50% or more.
Article
- Author:
- Neil Osterweil
Publish date: October 17, 2016
COPENHAGEN – The checkpoint inhibitor atezolizumab improved overall survival of advanced non–small-cell lung cancer, compared with doce...
Article
- Author:
- Neil Osterweil
Publish date: October 15, 2016
Cabozantinib offered longer progression-free survival than did sunitinib in first-line therapy for intermediate or poor-risk advanced RCC.
Article
- Author:
- Neil Osterweil
Publish date: October 14, 2016
COPENHAGEN – In patients with high-risk locoregional clear cell renal cell (RCC) carcinoma, adjuvant therapy with sunitinib significantly prolonged...
Article
- Author:
- Neil Osterweil
Publish date: October 14, 2016
Among patients with recurrent or metastatic squamous cell carcinoma of the head and neck, those treated with the programmed death ligand–1 ch...
Article
- Author:
- Neil Osterweil
Publish date: October 14, 2016
Interim results from a randomized trial show that combination chemotherapy with an anthracycline and an alkylating agent offers both a relapse-free...
Article
- Author:
- Neil Osterweil
Publish date: October 13, 2016
COPENHAGEN – Adding the PD-1 checkpoint inhibitor pembrolizumab (Keytruda) to a standard platinum-doublet chemotherapy regimen nearly doubled...
Article
- Author:
- Neil Osterweil
Publish date: October 12, 2016
COPENHAGEN – Five years on, patients with high-risk stage III melanoma treated with the checkpoint inhibitor ipilimumab, following complete r...
Article
- Author:
- Neil Osterweil
Publish date: October 12, 2016
COPENHAGEN – Women with platinum-sensitive, recurrent ovarian cancer treated with the PARP 1/2 inhibitor niraparib had significantly longer p...
